Stryker reported a Q2 recovery from the cyber incident with 9% organic growth and raised the low end of its full-year guidance to 8.3-9.3%. While the company expresses high confidence in the back-half ramp, it requires a significant acceleration. Key themes include resilience in capital demand, a return to share buybacks, and continued challenges in the peripheral vascular business. Q2 organic sales +9%, driven by strong med-surg/neuro and ortho performance.
Stryker reported a Q2 recovery from the cyber incident with 9% organic growth and raised the low end of its full-year guidance to 8.3-9.3%. While the company expresses high confidence in the back-half ramp, it requires a significant acceleration. Key themes include resilience in capital demand, a return to share buybacks, and continued challenges in the peripheral vascular business. Q2 organic sales +9%, driven by strong med-surg/neuro and ortho performance.
Stryker reported a Q2 recovery from the cyber incident with 9% organic growth and raised the low end of its full-year guidance to 8.3-9.3%. While the company expresses high confidence in the back-half ramp, it requires a significant acceleration. Key themes include resilience…
Kevin Lobo repeatedly expressed confidence in second-half delivery, cited zero order cancellations, and framed guidance as set with great comfort in the team's ability to execute.
Full-year organic sales guide narrowed to 8.3-9.3%, with EPS of $14.95-$15.10.
Management expresses high confidence in back-half acceleration, underpinned by strong capital orders and production ramp.
Capital order book strong, zero cancellations seen. Kevin Lobo repeatedly expressed confidence in second-half delivery, cited zero order cancellations, and framed guidance as set with great comfort in the team's ability to execute.
Management did not discuss financial capex; the focus was operational capacity. They are adding shifts and ramping production to work through an elevated capital backlog, with confidence that this supports a stronger second half.
Kevin Lobo repeatedly expressed confidence in second-half delivery, cited zero order cancellations, and framed guidance as set with great comfort in the team's ability to execute.
“Additionally, we recently received approval and have initiated a limited launch for our Pangea trauma plating system in Europe to be followed by a full commercial launch during the fourth quarter.”
“when we look at what's left to do with the rest of the year and where we are with our products and with the markets right now, We felt like it was a prudent range to be in the 8.3 to 9.3”
“considering our elevated level of cash flow generation, and recent valuation compression across the MedTech sector, we plan to resume share repurchases this quarter.”
“we have an elevated backlog as we exit the quarter. We've seen zero cancellations in our order books”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $14.95–$15.10 | $15.02 | MAINTAINED |
| Gross margin | FY2026 | 66% | 66% | GUIDED |
| Op margin | FY2026 | 27.4% | 27.4% | GUIDED |
| Revenue | FY2026 | 8.3%–9.3% | 8.8% | RAISED |